{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"28.51","upperLimit":"36.09","value":"31.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"352"}],"units":"Participants"}],"title":"Week 18"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"29.37","upperLimit":"39.06","value":"35.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"335"}],"units":"Participants"}],"title":"Week 30"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"34.44","upperLimit":"48.15","value":"42.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"320"}],"units":"Participants"}],"title":"Week 42"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"39.93","upperLimit":"53.61","value":"46.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"299"}],"units":"Participants"}],"title":"Week 54"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"38.26","upperLimit":"55.56","value":"49.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"282"}],"units":"Participants"}],"title":"Week 66"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"43.88","upperLimit":"61.58","value":"51.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"252"}],"units":"Participants"}],"title":"Week 78"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"47.37","upperLimit":"67.01","value":"57.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"222"}],"units":"Participants"}],"title":"Week 90"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"52.13","upperLimit":"70.94","value":"59.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"191"}],"units":"Participants"}],"title":"Week 102"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"361"}],"units":"Participants"}],"description":"Percentage change from start of everolimus in average weekly seizure frequency (SFcfe) = 100 × (SFe - SFtw) ÷ SFe where:\n\nSFe is the average weekly seizure frequency in the 8-week period before start of everolimus SFtw is the average weekly seizure frequency in a 12-week time window A positive percentage change from start of everolimus (SFcfe) means a reduction in seizure frequency whereas a negative percentage change from start of everolimus (SFcfe) means an increase in seizure frequency.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"},{"description":"Participants who were treated with everolimus either in the Core or Extension phases of the study and were evaluated for longer term safety and efficacy.","id":"OG003","title":"Everolimus Long Term Evaluation (LTE)"}],"paramType":"MEDIAN","populationDescription":"The LTE Efficacy Set included 361 patients who received at least one dose of everolimus in Core and Extension phase and had at least one valid postbaseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Baseline (8-week period before start of everolimus), Week 7 to 18, Week 19 to 30, and 12 weeks thereafter up to Week 102","title":"Long Term Evaluation: Percentage Change From Start of Everolimus in Seizure Frequency by Time Window","type":"SECONDARY","unitOfMeasure":"Percent change"}